No Clinically Significant Direct Interaction Between Tenofovir and Posaconazole
There is no documented direct pharmacokinetic or pharmacodynamic interaction between tenofovir and posaconazole that requires specific management or monitoring beyond standard practices for each drug individually.
Mechanism Analysis
Tenofovir Disposition
- Tenofovir is primarily renally eliminated and is a substrate of P-glycoprotein (P-gp) transporters 1, 2
- Not significantly metabolized by CYP450 enzymes
- Main concern is renal toxicity, particularly proximal tubular dysfunction 3
Posaconazole Disposition
- Posaconazole is metabolized via UDP-glucuronosyltransferase and is a substrate of P-gp 4
- Acts as a strong CYP3A4 inhibitor but does not affect P-gp-mediated transport of other drugs in a clinically meaningful way 4
- Does not induce or inhibit renal transporters relevant to tenofovir elimination
Why No Interaction Occurs
The evidence shows posaconazole increases exposure of drugs that are CYP3A4 substrates (tacrolimus, cyclosporine, sirolimus, statins, calcium channel blockers) 4, 5. However, tenofovir is not metabolized by CYP3A4. While both drugs interact with P-gp, posaconazole does not significantly inhibit P-gp in a way that would increase tenofovir absorption or decrease its renal elimination 4, 6.
Monitoring Recommendations
Monitor each drug independently based on their individual risk profiles:
For Tenofovir 3:
- Baseline and periodic renal function monitoring (serum creatinine, eGFR)
- Check for proximal tubular dysfunction markers if GFR declines:
- Euglycemic glycosuria
- Hypophosphatemia with increased urinary phosphorus
- New or worsening proteinuria
- Discontinue tenofovir if GFR decreases >25% from baseline AND falls to <60 mL/min/1.73m², especially with evidence of tubular dysfunction
- More frequent monitoring if patient has preexisting CKD or is receiving other nephrotoxic drugs
For Posaconazole 7, 8, 9:
- Therapeutic drug monitoring (TDM) is recommended for all formulations, despite manufacturer claims
- Target trough: ≥1000 ng/mL for prophylaxis, ≥1300 ng/mL for treatment
- Check first steady-state level at day 7, then weekly until stable
- 47.9% of patients fail to achieve target levels ≥1300 ng/mL with standard dosing 9
- Monitor for hepatotoxicity (most common adverse effect at 9.1%) 4
- Review all concomitant medications for CYP3A4 substrate interactions 4
Critical Caveat: Indirect Interaction Risk
The only scenario requiring heightened vigilance is when tenofovir is combined with ritonavir- or cobicistat-boosted antiretrovirals PLUS posaconazole 1. In this three-drug scenario:
- Ritonavir/cobicistat (which are CYP3A4 inhibitors) increase tenofovir exposure via P-gp inhibition
- Adding posaconazole does not further worsen this interaction
- However, intensify renal monitoring if this combination is unavoidable (check renal function every 2-4 weeks initially)
Common Pitfalls to Avoid
- Do not empirically reduce tenofovir dose when starting posaconazole—no interaction exists
- Do not assume posaconazole delayed-release tablets don't need TDM—recent data shows 28.8% have subtherapeutic levels <1000 ng/mL 9
- Do not overlook other drug interactions with posaconazole (particularly calcineurin inhibitors, statins, benzodiazepines) 4, 5
- Consider tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) in elderly patients or those with renal concerns, as TAF has lower systemic tenofovir exposure 1, 10